DK0559884T4 - Rekombinante virusvektorer til ekspression i muskelceller - Google Patents
Rekombinante virusvektorer til ekspression i muskelcellerInfo
- Publication number
- DK0559884T4 DK0559884T4 DK92921684T DK92921684T DK0559884T4 DK 0559884 T4 DK0559884 T4 DK 0559884T4 DK 92921684 T DK92921684 T DK 92921684T DK 92921684 T DK92921684 T DK 92921684T DK 0559884 T4 DK0559884 T4 DK 0559884T4
- Authority
- DK
- Denmark
- Prior art keywords
- muscle cells
- expression
- vectors
- viral vectors
- recombinant viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9111947A FR2681786A1 (fr) | 1991-09-27 | 1991-09-27 | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
PCT/FR1992/000898 WO1993006223A1 (fr) | 1991-09-27 | 1992-09-25 | Vecteurs recombinants viraux pour l'expression dans des cellules musculaires |
Publications (2)
Publication Number | Publication Date |
---|---|
DK0559884T3 DK0559884T3 (da) | 2000-10-02 |
DK0559884T4 true DK0559884T4 (da) | 2004-08-02 |
Family
ID=9417378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92921684T DK0559884T4 (da) | 1991-09-27 | 1992-09-25 | Rekombinante virusvektorer til ekspression i muskelceller |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0559884B2 (pt) |
JP (1) | JP3487597B2 (pt) |
AT (1) | ATE192500T1 (pt) |
AU (1) | AU666142B2 (pt) |
CA (1) | CA2097185C (pt) |
DE (1) | DE69230993T3 (pt) |
DK (1) | DK0559884T4 (pt) |
ES (1) | ES2147553T5 (pt) |
FR (1) | FR2681786A1 (pt) |
GR (1) | GR3034094T3 (pt) |
SG (1) | SG49081A1 (pt) |
WO (1) | WO1993006223A1 (pt) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5538722A (en) * | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
WO1994010322A1 (en) * | 1992-10-29 | 1994-05-11 | Board Of Regents, The University Of Texas System | Adenovirus-mediated ldl receptor gene transfer and targeting |
WO1994011506A1 (en) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
US6133028A (en) * | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US6730507B1 (en) | 1993-06-24 | 2004-05-04 | Merck & Co., Inc. | Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration |
EP0705344B8 (en) * | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
US6120764A (en) * | 1993-06-24 | 2000-09-19 | Advec, Inc. | Adenoviruses for control of gene expression |
US5919676A (en) * | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
US6080569A (en) * | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
US7045347B2 (en) | 1993-06-24 | 2006-05-16 | Advec, Inc. | Helper dependent adenovirus vectors based on integrase family site-specific recombinases |
US20020136708A1 (en) | 1993-06-24 | 2002-09-26 | Graham Frank L. | System for production of helper dependent adenovirus vectors based on use of endonucleases |
US6140087A (en) * | 1993-06-24 | 2000-10-31 | Advec, Inc. | Adenovirus vectors for gene therapy |
HU216871B (hu) * | 1993-07-13 | 1999-09-28 | Rhone-Poulenc Rorer S.A. | Defektív adenovírusvektorok és génterápiai alkalmazásuk |
FR2707664B1 (fr) * | 1993-07-13 | 1995-09-29 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2718749B1 (fr) * | 1994-04-18 | 1996-05-31 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2712812B1 (fr) * | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
US6379943B1 (en) | 1999-03-05 | 2002-04-30 | Merck & Co., Inc. | High-efficiency Cre/loxp based system for construction of adenovirus vectors |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
CA2188575A1 (en) | 1995-02-28 | 1996-09-06 | H. Kirk Hammond | Gene transfer-mediated angiogenesis therapy |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
US6974694B2 (en) | 1995-06-07 | 2005-12-13 | Advec, Inc. | Adenoviruses for control of gene expression |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
US5866552A (en) * | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
KR20010020571A (ko) | 1997-06-30 | 2001-03-15 | 자끄 사비나 | 횡문근중으로 개선된 핵산 전달방법 및 이를 위한콤비네이션 |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
AU9363798A (en) | 1997-11-06 | 1999-05-31 | Chiron S.P.A. | Neisserial antigens |
CA2317815A1 (en) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Neisseria meningitidis antigens |
AU767662B2 (en) | 1998-02-06 | 2003-11-20 | Collateral Therapeutics, Inc. | Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF |
ES2304065T3 (es) | 1998-05-01 | 2008-09-01 | Novartis Vaccines And Diagnostics, Inc. | Antigenos y composiciones de neisseria meningitidis. |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
AU1316200A (en) | 1998-10-15 | 2000-05-01 | Chiron Corporation | Metastatic breast and colon cancer regulated genes |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
PT1141331E (pt) | 1998-12-16 | 2008-12-22 | Novartis Vaccines & Diagnostic | Quinase dependente de ciclina humana (hpnqalre) |
EP1721982B1 (en) | 1999-04-15 | 2013-04-10 | Boehringer Ingelheim Vetmedica GmbH | Chimeric lyssavirus nucleic acids and polypeptides |
US6673601B1 (en) | 1999-04-15 | 2004-01-06 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
NZ581940A (en) | 1999-04-30 | 2011-07-29 | Novartis Vaccines & Diagnostic | Conserved neisserial antigens |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
RU2281956C2 (ru) | 1999-10-29 | 2006-08-20 | Чирон С.Р.Л. | Антигенные пептиды neisseria |
DK2289545T3 (en) | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
CN100473663C (zh) | 2000-02-28 | 2009-04-01 | 启龙股份公司 | 奈瑟球菌蛋白质的异源表达 |
US7238672B1 (en) | 2000-04-17 | 2007-07-03 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
EP1191104A1 (en) * | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
CN1526014A (zh) * | 2000-10-06 | 2004-09-01 | ��ʽ���������о��� | 用于将外源基因导入骨骼肌的副粘病毒载体 |
EP2189473A3 (en) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic and proteins from streptococcus groups A & B |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
FR2829136B1 (fr) | 2001-08-29 | 2006-11-17 | Aventis Pharma Sa | Derives lipidiques d'aminoglycosides |
JP4413617B2 (ja) | 2001-12-12 | 2010-02-10 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Chlamydiatrachomatisに対する免疫化 |
PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
JP4792390B2 (ja) | 2004-03-29 | 2011-10-12 | 株式会社ガルファーマ | 新規ガレクチン9改変体タンパク質及びその用途 |
AU2005294265A1 (en) | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
EP1856526A4 (en) | 2005-01-20 | 2008-11-12 | Univ Rochester | THIOREDOXIN-INTERACTING PROTEIN (TXNIP) AS REGULATOR OF VASCULAR FUNCTION |
US8026354B2 (en) | 2005-11-23 | 2011-09-27 | Institut Pasteur | Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
PT2054431E (pt) | 2006-06-09 | 2011-11-03 | Novartis Ag | Confórmeros de adesinas bacterianas |
US8673859B2 (en) | 2007-03-20 | 2014-03-18 | New York University | GM-CSF cosmeceutical compositions and methods of use thereof |
US8790664B2 (en) | 2008-09-05 | 2014-07-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Multimodular assembly useful for intracellular delivery |
US8772238B2 (en) | 2009-03-18 | 2014-07-08 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer |
EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
EP2658567A4 (en) | 2010-12-28 | 2014-09-24 | Univ Rochester | METHOD FOR MODIFYING INSULIN SIGNAL TRANSMISSION BY BILIVERDINREDUCTASE (BVR) AND BVR-DERIVED PEPTIDES |
DK2753346T3 (da) | 2011-09-07 | 2020-05-25 | Sinai School Medicine | Ceramidase og celledifferentiering |
US9694050B2 (en) | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
WO2014176259A1 (en) | 2013-04-22 | 2014-10-30 | Icahn School Of Medicine At Mount Sinai | Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis |
EP3371211A4 (en) | 2015-11-04 | 2019-08-21 | Icahn School of Medicine at Mount Sinai | METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT |
WO2017189730A1 (en) | 2016-04-26 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU576907B2 (en) * | 1984-11-01 | 1988-09-08 | American Home Products Corporation | Oral vaccines comprising live recombinant adenoviruses |
FR2573436B1 (fr) * | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
ATE132534T1 (de) * | 1986-08-01 | 1996-01-15 | Commw Scient Ind Res Org | Rekombinanter impfstoff |
DE69032284T2 (de) * | 1989-03-21 | 1998-10-08 | Vical, Inc., San Diego, Calif. | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
AU647391B2 (en) * | 1989-05-01 | 1994-03-24 | University Of Notre Dame Du Lac, The | Methods and materials for expression of human plasminogen in a eukaryotic cell system |
GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
-
1991
- 1991-09-27 FR FR9111947A patent/FR2681786A1/fr active Granted
-
1992
- 1992-09-25 SG SG1996005855A patent/SG49081A1/en unknown
- 1992-09-25 ES ES92921684T patent/ES2147553T5/es not_active Expired - Lifetime
- 1992-09-25 AU AU27902/92A patent/AU666142B2/en not_active Expired
- 1992-09-25 CA CA002097185A patent/CA2097185C/fr not_active Expired - Lifetime
- 1992-09-25 DE DE69230993T patent/DE69230993T3/de not_active Expired - Lifetime
- 1992-09-25 EP EP92921684A patent/EP0559884B2/fr not_active Expired - Lifetime
- 1992-09-25 AT AT92921684T patent/ATE192500T1/de active
- 1992-09-25 WO PCT/FR1992/000898 patent/WO1993006223A1/fr active IP Right Grant
- 1992-09-25 DK DK92921684T patent/DK0559884T4/da active
- 1992-09-25 JP JP50585393A patent/JP3487597B2/ja not_active Expired - Lifetime
-
2000
- 2000-08-02 GR GR20000401791T patent/GR3034094T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2147553T3 (es) | 2000-09-16 |
GR3034094T3 (en) | 2000-11-30 |
ES2147553T5 (es) | 2004-11-16 |
JP3487597B2 (ja) | 2004-01-19 |
CA2097185A1 (fr) | 1993-03-28 |
AU666142B2 (en) | 1996-02-01 |
EP0559884A1 (fr) | 1993-09-15 |
DE69230993T2 (de) | 2000-11-30 |
JPH06502771A (ja) | 1994-03-31 |
CA2097185C (fr) | 2007-07-24 |
EP0559884B2 (fr) | 2004-04-07 |
DE69230993D1 (de) | 2000-06-08 |
FR2681786A1 (fr) | 1993-04-02 |
WO1993006223A1 (fr) | 1993-04-01 |
FR2681786B1 (pt) | 1995-05-12 |
DK0559884T3 (da) | 2000-10-02 |
AU2790292A (en) | 1993-04-27 |
DE69230993T3 (de) | 2004-12-16 |
ATE192500T1 (de) | 2000-05-15 |
SG49081A1 (en) | 1998-05-18 |
EP0559884B1 (fr) | 2000-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0559884T3 (da) | Rekombinante virusvektorer til ekspression i muskelceller | |
DE3684892D1 (de) | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens. | |
IT1206311B (it) | Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso. | |
ES8607391A1 (es) | Procedimiento para producir un fragmento de dna que compren-de un promotor de fosfatasa acida de levadura | |
BR0010725A (pt) | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc | |
DE69518910T2 (de) | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle | |
DE69637874D1 (de) | C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2 | |
DK0910647T3 (da) | Human DNase i hyperaktive varianter | |
MX9301700A (es) | Muteinas del factor de necrosis tumoral humano, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
HUP0003563A2 (hu) | Aminoterminálisa felől csonkolt MCP-2 mint kemokinantagonista | |
ATE246247T1 (de) | Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität | |
KR870003792A (ko) | 백혈구 감소증치료제 | |
NZ331063A (en) | Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition | |
BR9812138A (pt) | Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta | |
ATE43139T1 (de) | Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon. | |
DK0811068T3 (da) | Humane DNase I varianter | |
DE69730967D1 (en) | Human dnase ii | |
DE69306273D1 (de) | Mitogen für die glatte Muskulatur und dessen kodierende DNS | |
ATE55411T1 (de) | Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen. | |
EP0218432A3 (en) | Methods for cdna cloning, and vector-primer dna, plasmid dna and linker dna, used in the said methods | |
AR242636A1 (es) | Gen con codificacion para actividad de factor estimulante de colonias de granulocitos humanos. | |
MX9706429A (es) | Variantes de dnasa i humana. |